Related Experiment Video
Updated: Jun 24, 2025
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Next-level precision medicine: why the theragnostic approach is the future
Aniello Iacomino1, Marco Rapa2, Gianluca Gatta2
1Guglielmo Marconi University of Rome, Rome, Italy.
Abstract:
Theragnostics represents one of the most innovative fields of precision medicine with a huge potential in the field of oncology in the next years. The use of a pair of selective radiopharmaceuticals for cellular receptors, used for diagnostic and therapeutic purposes (PRRT), finds applications in the Neuroendocrine tumors and metastatic Castration-Resistant prostate cancer (mCRPC) thanks, respectively, to somatostatin receptor agonists and PSMA-based peptides. Further evolutions of theragnostics will be possible to the radioimmunoconjugates used both in the diagnostic (Immuno-PET) and in the therapeutic fields (radioimmunotherapy). It is evident that in the "omics-era," theragnostics could become a necessary method, not only in order to improve our knowledge of tumor biology, but also, to find more and more targeted therapies in a multidisciplinary context and in a tailor-based approach.
Insights
Theragnostics, combining diagnostic and therapeutic applications, offers precision medicine for oncology. Future advancements include radioimmunoconjugates for targeted cancer therapies.
Area of Science:
- Oncology
- Precision Medicine
- Radiopharmaceuticals
Background:
- Theragnostics is a rapidly advancing field in precision medicine with significant oncological potential.
- Selective radiopharmaceuticals are utilized for both diagnostic and therapeutic purposes, particularly in neuroendocrine tumors and metastatic castration-resistant prostate cancer (mCRPC).
Purpose of the Study:
- To explore the innovative field of theragnostics in oncology.
- To highlight the current and future applications of radiopharmaceuticals and radioimmunoconjugates in cancer treatment.
Main Methods:
- Utilizing somatostatin receptor agonists for neuroendocrine tumors.
- Employing PSMA-based peptides for mCRPC.
- Exploring radioimmunoconjugates for diagnostic imaging (Immuno-PET) and therapeutic radioimmunotherapy.
Main Results:
- Personalized Peptide Receptor Radionuclide Therapy (PRRT) demonstrates efficacy in specific cancers.
- Radioimmunoconjugates represent a promising evolution for enhanced diagnostic and therapeutic capabilities.
- Theragnostics facilitates a deeper understanding of tumor biology and the development of targeted therapies.
Conclusions:
- Theragnostics is crucial for advancing precision oncology.
- The integration of theragnostics into the 'omics-era' supports multidisciplinary, tailored cancer treatment approaches.
- Continued innovation in radiopharmaceuticals and radioimmunoconjugates will drive the future of targeted cancer therapy.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...